Introduction {#sec1-0300060519855869}
============

Hepatocellular carcinoma (HCC) has a high degree of malignancy and a poor prognosis. The highest worldwide incidences of HCC are in Asia and Africa; about 75% of HCCs occur in Asia.^[@bibr1-0300060519855869]^ Chronic hepatitis B and hepatitis C virus infections are major risk factors for HCC, but only 10% of individuals infected with these viruses eventually develop HCC.^[@bibr2-0300060519855869],[@bibr3-0300060519855869]^ Therefore, genetic and environmental factors may be involved in the occurrence and development of HCC.

The human multidrug resistance 1 gene (*MDR1*) is located on the long arm of chromosome 7 and contains 28 exons. The intron and exon junctions conform to the classical A/G rule and have a full length of 4.5 kb. An open reading frame encoding a 1280-amino acid polypeptide is glycosylated to form a 170-kDa membrane glycoprotein (P-glycoprotein), which plays a physiological role in protecting cells from toxin and metabolite damage.^[@bibr4-0300060519855869]^ Recent studies have found that *MDR1* polymorphism is not only an important genetic factor affecting the response of cancer patients to chemotherapy drugs but is also related to patients' susceptibility to disease and clinical manifestations.^[@bibr5-0300060519855869][@bibr6-0300060519855869]--[@bibr7-0300060519855869]^

A relationship between polymorphism rs1128503 or rs1045642 of the *MDR1* gene and susceptibility to HCC has been reported but the conclusions are inconsistent. Therefore, we performed this study to objectively evaluate the relationship between HCC and *MDR1* polymorphisms rs1128503 and rs1045642 by meta-analysis. We aimed to explore the significance of *MDR1* polymorphisms rs1128503 and rs1045642 in HCC screening and diagnosis.

Material and methods {#sec2-0300060519855869}
====================

Inclusion and exclusion criteria {#sec3-0300060519855869}
--------------------------------

The inclusion criteria for this study were as follows: (1) a case control study; (2) clinical study to evaluate the relationship between rs1128503 and rs1045642 polymorphisms of *MDR1* and the risk of HCC; and (3) sufficient data, including the number of subjects and gene frequency.

The exclusion criteria for this study were as follows: (1) meeting summary, case report, or review article; (2) relationship between *MDR1* rs1128503 and rs1045642 polymorphisms and HCC risk was not detected; or (3) a study with repeatedly reported data or unclear data.

Literature retrieval {#sec4-0300060519855869}
--------------------

Three foreign language databases, PubMed, Cochrane, and Embase, and three Chinese databases, Wanfang, China National Knowledge Infrastructure (CNKI), and China Knowledge Network, were comprehensively searched by the method of retrospection. The retrieval date ended on August 23, 2018. We used the following combined keywords and MeSH terms: "ABCB1, C3435T, C1236T, rs1128503, rs1045642, MDR1, MDR-1, p-glycoprotein, P-gp" and "polymorphism, SNP, variation, variants, locus, mutation" and "liver cancer, liver tumor, liver tumour, liver malignance, liver carcinoma, liver neoplasm, hepatocellular carcinoma, HCC, intrahepatic cholangiocarcinoma, ICC, hepato-cholangio-carcinoma, HCC-CC, hepatoma".

Literature extraction and filtering and evaluation of data quality {#sec5-0300060519855869}
------------------------------------------------------------------

Evaluation of the extracted publications was carried out by two independent researchers; if there was disagreement, a third researcher was included in the evaluation until consensus was reached. The retrieved publications were screened according to the preset inclusion and exclusion criteria, reviewing title, abstract, and full text systematically. Data extracted included first author, publication year, country, number of subjects and gene distribution, type of adverse reactions, source of controls, ethnicity, and Hardy-Weinberg equilibrium (HWE) test. The quality of the included studies was assessed using the Newcastle-Ottawa scale (NOS).

Statistical analysis {#sec6-0300060519855869}
--------------------

Statistical analysis was performed using Stata 13.0 (StataCorp LLC, College Station, TX, USA) for data processing, and heterogeneity among the studies was analyzed using the Q test and *P*-value, and heterogeneity was evaluated by *I*^2^. When *P* ≥ 0.1 or *I*^2^ ≤ 50%, there was no statistical heterogeneity among the studies and the fixed-effect model was used for combined analysis. When *P* \< 0.1 or *I*^2^ \> 50%, there was statistical heterogeneity among studies, and the combined analysis was performed using the random-effect model. The odds ratio (OR) value and 95% confidence interval (CI) were analyzed as the combined effect value with a test level α = 0.05. Potential publication bias was analyzed by using Egger's test, and sensitivity analysis was performed if necessary.

Results {#sec7-0300060519855869}
=======

Literature search and screening results {#sec8-0300060519855869}
---------------------------------------

According to the search strategy, 290 publications were initially retrieved. After 47 duplicates were excluded, 213 unrelated articles and 25 publications with insufficient data or non-*MDR1* polymorphisms and HCC risk were excluded by reading the title, abstract, and full text. A total of 5 qualified publications were screened and included in the meta-analysis^[@bibr8-0300060519855869][@bibr9-0300060519855869][@bibr10-0300060519855869][@bibr11-0300060519855869]--[@bibr12-0300060519855869]^ ([Figure 1](#fig1-0300060519855869){ref-type="fig"}).

![Flow diagram of study selection process.](10.1177_0300060519855869-fig1){#fig1-0300060519855869}

Basic characteristics and quality evaluation of the included studies {#sec9-0300060519855869}
--------------------------------------------------------------------

After the studies included in the literature were integrated and differentiated, 7 studies were available from 5 publications for analysis in this study. Of these, 4 studies were on the rs1128503 polymorphism and HCC susceptibility, and 3 studies were on the rs1045642 locus. The quality of the studies was scored using the NOS, and the results ranged from 5 to 9 points, indicating that the included studies were of medium to high quality ([Table 1](#table1-0300060519855869){ref-type="table"}, [Figure 2](#fig2-0300060519855869){ref-type="fig"}).

![Quality assessment scale of eligible studies.](10.1177_0300060519855869-fig2){#fig2-0300060519855869}

###### 

Characteristics of studies on the associations between rs1128503 (T \> C) and rs1045642 (T \> C) polymorphisms in *MDR1* and hepatocellular cancer.

![](10.1177_0300060519855869-table1)

  Author   Year   Country   Ethnicity   *MDR1* type   Source of controls   Control type   Cases   Controls   Cases   Controls   HWE   NOS                      
  -------- ------ --------- ----------- ------------- -------------------- -------------- ------- ---------- ------- ---------- ----- ----- ---- ---- -------- ---
  De       2017   Italy     Caucasian   rs1128503     HB                   HBV/HCV        192     167        46      92         54    22    93   52   0.15     7
                  Italy     Caucasian   rs1128503     PB                   Healthy        192     192        46      92         54    39    95   58   1.00     7
  Dong     2013   China     Asian       rs1045642     PB                   Healthy        109     109        16      45         48    22    47   40   0.50     8
  Jing     2013   China     Asian       rs1128503     PB                   Healthy        109     109        36      54         19    39    48   22   0.60     9
  Chen     2011   China     Asian       rs1128503     HB                   Cholecyst      36      50         15      6          15    24    14   12   0.02     6
                  China     Asian       rs1045642     HB                   Cholecyst      36      50         8       10         18    11    12   27   \<0.01   6
  Fukuda   2010   Japan     Asian       rs1045642     PB                   Healthy        58      61         13      29         16    8     39   14   0.08     6

HBV, hepatitis B virus; HCV, hepatitis C virus; HB, hospital-based; PB, population-based; WH, wild homozygous genotype; WM, wild/mutant heterozygous genotype; MH, mutant homozygous genotype; HWE, Hardy-Weinberg equilibrium; NOS, Newcastle-Ottawa scale.

Meta-analysis {#sec10-0300060519855869}
-------------

The association between susceptibility to HCC and two *MDR1* polymorphism sites (rs1128503 and rs1045642) was analyzed in an allele model (C vs. T), a homozygous model (CC vs. TT), a heterozygous model (CT vs. TT), a recessive model (CC vs. CT + TT), and a dominant model (CC + CT vs. TT), respectively. Four studies were included and we found no significant relation between *MDR1* rs1128503 polymorphism and susceptibility to HCC under the five genetic models ([Table 2](#table2-0300060519855869){ref-type="table"}, [Figure 3](#fig3-0300060519855869){ref-type="fig"}). Meta-analysis of *MDR1* rs1045642 polymorphism and susceptibility to HCC from 3 studies also showed no significant relation ([Table 2](#table2-0300060519855869){ref-type="table"}, [Figure 4](#fig4-0300060519855869){ref-type="fig"}). Racial subgroup analysis showed a relation between *MDR1* rs1128503 polymorphism and HCC risk in Caucasians (CC vs. TT: OR = 0.64, 95% CI = 0.42--0.98, *P* = 0.039, *I*^2^ = 12.4%; CT vs. TT: OR = 0.64, 95% CI = 0.44--0.94, *P* = 0.024, *I*^2^ = 48.2%; CC + CT vs. TT: OR = 0.64, 95% CI =0.45--0.93, *P* = 0.017, *I*^2^ = 47.4%). A subgroup analysis of control species showed a relation between *MDR1* rs1128503 polymorphism and HCC risk in patients with hepatitis virus infection and gallstones (CT vs. TT: OR = 0.51, 95% CI = 0.30--0.86, *P* = 0.011, *I*^2^ = 0.0%) ([Table 3](#table3-0300060519855869){ref-type="table"}).

![Forest plot of hepatocellular cancer risk associated with rs1128503 (C\>T) models. (a) allele model; (b) homozygous model; (c) heterozygous model; (d) recessive model; (e) dominant model. The horizontal line indicates the lower and upper limits of the 95% CI; the square indicates the OR, with the size of the square indicating the weight of the study and the dotted red line indicating the combined OR value. The diamond represents the combined effect size, and the larger the diamond, the larger the confidence interval. A cross between the diamond and the ineffective line indicates no statistical correlation between the factors studied and the outcome; if the diamond falls on the left side of the invalid vertical line, it indicates a protective factor; if the diamond falls on the right side of the line, it indicates a risk factor. OR, odds ratio; CI, confidence interval.](10.1177_0300060519855869-fig3){#fig3-0300060519855869}

![Forest plot of hepatocellular cancer risk associated with rs1045642 (C\>T) models. (a) allele model; (b) homozygous model; (c) heterozygous model; (d) recessive model; (e) dominant model. The horizontal line indicates the lower and upper limits of the 95% CI; the square indicates the OR, with the size of the square indicating the weight of the study and the dotted red line indicating the combined OR value. The diamond represents the combined effect size, and the larger the diamond, the larger the confidence interval. A cross between the diamond and the ineffective line indicates no statistical correlation between the factors studied and the outcome; if the diamond falls on the left side of the invalid vertical line, it indicates a protective factor; if the diamond falls on the right side of the line, it indicates a risk factor. OR, odds ratio; CI, confidence interval.](10.1177_0300060519855869-fig4){#fig4-0300060519855869}

###### 

OR and 95% CI for hepatocellular cancer and rs1128503 or rs1045642 polymorphism in *MDR1* under different genetic models.

![](10.1177_0300060519855869-table2)

  Genetic models                    n   OR (95% CI)         *P* (OR)   Analysis model   *I^2^*(%)   *P*(H)   *P* (Egger)   *P* (Begg)
  --------------------------------- --- ------------------- ---------- ---------------- ----------- -------- ------------- ------------
  rs1128503 T\>C                                                                                                           
   Allele (C vs. T)                 4   0.91 (0.76, 1.08)   0.260      F (M-H)          42.8        0.155    0.082         0.308
   Homozygous model (CC vs. TT)     4   0.80 (0.57, 1.12)   0.193      F (M-H)          46.2        0.134    0.225         0.308
   Heterozygous model (CT vs. TT)   4   0.77 (0.56, 1.04)   0.093      F (M-H)          40.5        0.169    0.914         1.000
   Recessive model (CC vs. CT+TT)   4   0.95 (0.73, 1.25)   0.729      F (M-H)          19.1        0.295    0.230         0.734
   Dominant model (CC+CT vs. TT)    4   0.81 (0.61, 1.07)   0.137      F (M-H)          48.5        0.120    0.592         0.734
  rs1045642 T\>C                                                                                                           
   Allele (C vs. T)                 3   1.10 (0.83, 1.45)   0.505      F (M-H)          0           0.435    0.293         1.000
   Homozygous model (CC vs. TT)     3   1.16 (0.67, 2.01)   0.587      F (M-H)          0           0.421    0.100         0.296
   Heterozygous model (CT vs. TT)   3   0.93 (0.55, 1.60)   0.800      F (M-H)          29.2        0.243    0.755         1.000
   Recessive model (CC vs. CT+TT)   3   1.21 (0.81, 1.80)   0.354      F (M-H)          0           0.660    0.481         0.296
   Dominant model (CC+CT vs. TT)    3   1.01 (0.62, 1.65)   0.962      F (M-H)          30.3        0.238    0.450         1.000

OR, odds ratio; CI, confidence interval; *P*(OR), probability for odds ratio; *P*(H), *P* for heterogeneity; n, number of the included studies; F, fixed-effect model; M-H, Mantel-Haenszel method.

###### 

Stratified analyses of relation between hepatocellular cancer and rs1128503 or rs1045642 polymorphism in *MDR1* under different genetic models.

![](10.1177_0300060519855869-table3)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Subgroup         N   Allele (C vs. T)   Homozygous model (CC vs. TT)   Heterozygous model (CT vs. TT)   Recessive model (CC vs. CT + TT)   Dominant model (CC + CT vs. TT)                                                                                             
  ---------------- --- ------------------ ------------------------------ -------------------------------- ---------------------------------- --------------------------------- ------ -------------- ------- ------ -------------- ------- ------ -------------- ------- ------
  rs1128503 T\>C                                                                                                                                                                                                                                                         

   Ethnicity                                                                                                                                                                                                                                                             

    Asian          2   1.15\              0.409                          43.4                             1.24\                              0.484                             29.0   1.06\          0.784   0.0    1.18\          0.543   65.3   1.18\          0.499   0.0
                       (0.83, 1.58)                                                                       (0.68, 2.26)                                                                (0.64, 1.82)                  (0.69, 2.03)                  (0.74, 1.88)           

    Caucasian      2   0.82\              0.063                          0.0                              0.64\                              0.039                             12.4   0.64\          0.024   48.2   0.89\          0.449   0.0    0.64\          0.017   47.4
                       (0.67, 1.01)                                                                       (0.42, 0.98)                                                                (0.44, 0.94)                  (0.65, 1.21)                  (0.45, 0.93)           

   Control type                                                                                                                                                                                                                                                          

    Healthy        2   0.93\              0.524                          0.0                              0.84\                              0.447                             0.0    0.97\          0.883   0.0    0.88\          0.510   0.0    0.93\          0.710   0.0
                       (0.74, 1.17)                                                                       (0.53, 1.32)                                                                (0.66,1.43)                   (0.61, 1.28)                  (0.65, 1.34)           

    Others         2   0.88\              0.324                          79.6                             0.75\                              0.269                             81.3   0.51\          0.011   0.0    1.04\          0.835   69.9   0.64\          0.058   71.7
                       (0.67, 1.14)                                                                       (0.44, 1.26)                                                                (0.30, 0.86)                  (0.70, 1.57)                  (0.40, 1.01)           

  rs1045642 T\>C                                                                                                                                                                                                                                                         

   Controls type                                                                                                                                                                                                                                                         

    Healthy        2   1.15\              0.379                          20.2                             1.26\                              0.473                             32.7   0.89\          0.702   63.0   1.33\          0.214   0.0    1.02\          0.946   65.1
                       (0.84, 1.56)                                                                       (0.67, 2.36)                                                                (0.49, 1.61)                  (0.85, 2.10)                  (0.58, 1.78)           

    others         1   0.91\              0.774                          NU                               0.92\                              0.876                             NU     1.15\          0.829   NU     0.85\          0.714   NU     0.99\          0.980   NA
                       (0.48, 1.72)                                                                       (0.31, 2.72)                                                                (0.33, 3.95)                  (0.36, 2.01)                  (0.35, 2.77)           
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

N, number of comparisons; OR, odds ratio; CI, confidence interval; NU, null, NA, not available.

Publication bias and sensitivity analysis {#sec11-0300060519855869}
-----------------------------------------

On the basis of the results of Egger's test, there was no publication bias in this study ([Table 2](#table2-0300060519855869){ref-type="table"}). To evaluate the stability of this meta-analysis, we excluded the included studies one by one and compared the differences between the effect values before and after each elimination. This analysis showed that the results were stable.

Discussion {#sec12-0300060519855869}
==========

The *MDR1* rs1128503 and rs1045642 polymorphisms are synonymous mutations in exon 26 and exon 12,^[@bibr13-0300060519855869]^ respectively, and the CC genotype in the mutation site is considered the wild type.^[@bibr14-0300060519855869]^ The wild-type P-glycoprotein not only pumps drugs out of cells but, synergistically with immune function, also inhibits tumorigenesis and development.^[@bibr15-0300060519855869]^ Some studies have found that P-glycoprotein can delay the apoptosis cascade of tumor cells by inhibiting caspase.^[@bibr16-0300060519855869]^ Five relevant studies were included in this meta-analysis, and the results showed that the rs1128503 polymorphism may be related to HCC risk in Caucasian individuals and in patients with hepatitis virus infection or gallstones.

A previous meta-analysis showed that mutations in the *MDR1* gene are associated with susceptibility to HCC and are risk factors for HCC.^[@bibr17-0300060519855869]^ The different results between that meta-analysis and the current meta-analysis may be explained by two factors. First, in the early study, the association analysis between *MDR1* polymorphisms and susceptibility to HCC was based on pooled results from 11 mutation sites in *MDR1*. In the current meta-analysis, the relation analysis between *MDR1* polymorphism and susceptibility to HCC was conducted for only two polymorphic sites. Second, the subjects included in the previous study were Asian (Japanese and Chinese), whereas those in the current analysis were Asian (Japanese and Chinese) and Caucasian (Italian). Compared with the previous study, a more appropriate detailed analysis of the relation between *MDR1* mutation and hepatocarcinogenesis, involving different populations, was performed in this meta-analysis, and the results were shown to be reliable.

The occurrence of HCC is a complex pathological process, involving multiple genes and environmental factors.^[@bibr18-0300060519855869][@bibr19-0300060519855869]--[@bibr20-0300060519855869]^ Hepatitis virus infection,^[@bibr21-0300060519855869],[@bibr22-0300060519855869]^ smoking,^[@bibr23-0300060519855869],[@bibr24-0300060519855869]^ drinking,^[@bibr25-0300060519855869],[@bibr26-0300060519855869]^ and genetic factors are non-negligible causes of HCC. These risk factors may cause chronic inflammation and accumulation of toxic products in the liver, leading to HCC.^[@bibr27-0300060519855869],[@bibr28-0300060519855869]^ The protein encoded by *MDR1* is involved in the elimination of endogenous and exogenous harmful substances.^[@bibr29-0300060519855869]^ Polymorphisms in *MDR1* will alter the structure or expression of the encoded protein, thereby affecting its efflux effect on carcinogens and the normal physiological functions of hepatocytes.^[@bibr30-0300060519855869]^ However, abnormal protein expression of *MDR1* also affects the sensitivity of cancer cells to drugs, thereby affecting the development of HCC.^[@bibr31-0300060519855869]^ In this meta-analysis, we analyzed the relationship between two mutations of *MDR1* and susceptibility to HCC without considering the influence of other factors. However, the number of subjects included in the current meta-analysis was limited, and the control group was included with different standards. Therefore, further stringent analyses with larger sample sizes are necessary to confirm the results of this meta-analysis.

In conclusion, this meta-analysis showed that *MDR1* polymorphism rs1128503 may be related to HCC risk in Caucasians and in patients with hepatitis viral infection or gallstones. A better understanding of the effect of *MDR1* gene polymorphisms on HCC risk by analyzing the relation between rs1128503 or rs1045642 and HCC might improve our understanding of the role of genetic factors in HCC risk.
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